Related references
Note: Only part of the references are listed.Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Asghar Fallah et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
Shunji Takahashi et al.
FUTURE ONCOLOGY (2019)
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer
Nidal Al-Huniti et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction
Takeshi Wada et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Tivozanib for the treatment of renal cell carcinoma
Matteo Santoni et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes
Karla B. Neves et al.
HYPERTENSION (2018)
Anti-Angiogenics: Current Situation and Future Perspectives
Katja Zirlik et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Left Ventricular Dysfunction in Cancer Treatment Is it Relevant?
Benjamin Kenigsberg et al.
JACC-HEART FAILURE (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience
Nilesh Pareek et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma A Case Report of Onco-Cardiology
Midori Takada et al.
INTERNATIONAL HEART JOURNAL (2018)
Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
Maher Chaar et al.
ONCOTARGETS AND THERAPY (2018)
Risk of regorafenib-induced cardiovascular events in patients with solid tumorsA systematic review and meta-analysis A systematic review and meta-analysis
Jianxin Chen et al.
MEDICINE (2018)
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
Joanne J. Carter et al.
FASEB JOURNAL (2017)
Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise Role of Interstitial Sodium Accumulation?
Stephanie Lankhorst et al.
HYPERTENSION (2017)
Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition
Rhian M. Touyz et al.
HYPERTENSION (2017)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sunitinib Induces NK-κB- dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells
Yu-xian Huang et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Modulation of VEGF receptor 2 signaling by protein phosphatases
Federico Corti et al.
PHARMACOLOGICAL RESEARCH (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions
Diwakar Jain et al.
CURRENT CARDIOLOGY REPORTS (2017)
Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes
Ivan Kopljar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis
Bo Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Quality of Life With Cediranib in Relapsed Ovarian Cancer: The ICON6 Phase 3 Randomized Clinical Trial
Dan P. Stark et al.
CANCER (2017)
miRNAs: micro-managers of anticancer combination therapies
Judy R. van Beijnum et al.
ANGIOGENESIS (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Husam Abdel-Qadir et al.
CANCER TREATMENT REVIEWS (2017)
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System
Antonella Moreo et al.
AMERICAN JOURNAL OF HYPERTENSION (2016)
Endothelin-1 and antiangiogenesis
Stephanie Lankhorst et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2016)
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond
Rohit Moudgil et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Al B. Benson et al.
CLINICAL CANCER RESEARCH (2016)
Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art
Sandro Barni et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma
Elaine McWhirter et al.
INVESTIGATIONAL NEW DRUGS (2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann et al.
LANCET (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vascularization and Angiogenesis in Tissue Engineering: Beyond Creating Static Networks
Jeroen Rouwkema et al.
TRENDS IN BIOTECHNOLOGY (2016)
VEGF and Intraocular Neovascularization: From Discovery to Therapy
Napoleone Ferrara
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2016)
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
J. S. L. Kloth et al.
BRITISH JOURNAL OF CANCER (2015)
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2015)
Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib
Stephanie Lankhorst et al.
HYPERTENSION (2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle et al.
LANCET ONCOLOGY (2015)
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
R. Paul Symonds et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs
Nihay Laham-Karam et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
P. Ghatalia et al.
BRITISH JOURNAL OF CANCER (2015)
Elevated Blood Pressure in Preterm-Born Offspring Associates With a Distinct Antiangiogenic State and Microvascular Abnormalities in Adult Life
Adam J. Lewandowski et al.
HYPERTENSION (2015)
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
T. Dragovich et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma
Rhonda L. Bitting et al.
CLINICAL GENITOURINARY CANCER (2014)
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
S. A. Laurie et al.
EUROPEAN JOURNAL OF CANCER (2014)
Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial
Amikumar Mehta et al.
FUTURE ONCOLOGY (2014)
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2014)
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2014)
AKT2 Confers Protection Against Aortic Aneurysms and Dissections
Ying H. Shen et al.
CIRCULATION RESEARCH (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Javid Moslehi et al.
CIRCULATION (2010)
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Hui Cheng et al.
CIRCULATION RESEARCH (2010)
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor-Signaling Inhibitors
Emily S. Robinson et al.
HYPERTENSION (2010)
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Dhanalakshmi Chinnasamy et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
Angela Coxon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
Jane D. Robertson et al.
CLINICAL COLORECTAL CANCER (2009)
Cardiovascular toxicity of molecularly targeted agents
Elizabeth L. Strevel et al.
EUROPEAN JOURNAL OF CANCER (2009)
COX-2, VEGF AND TUMOUR ANGIOGENESIS
D. P. Toomey et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2009)
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
Leticia Oliveira-Ferrer et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
Sun Hwa Kim et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Share Paper
